Intensity Therapeutics In... (INTS)
| Bid | 0.52 |
| Market Cap | 8.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.27M |
| EPS (ttm) | -1.17 |
| PE Ratio (ttm) | -0.48 |
| Forward PE | -0.66 |
| Analyst | Buy |
| Ask | 0.6 |
| Volume | 231,425 |
| Avg. Volume (20D) | 121,642 |
| Open | 0.59 |
| Previous Close | 0.59 |
| Day's Range | 0.55 - 0.60 |
| 52-Week Range | 0.50 - 5.28 |
| Beta | 4.59 |
About INTS
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & D...
Analyst Forecast
According to 3 analyst ratings, the average rating for INTS stock is "Buy." The 12-month stock price forecast is $8.5, which is an increase of 1416.23% from the latest price.
Stock Forecasts
11 months ago · seekingalpha.com
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology DrugMid-2024, Intensity Therapeutics will start Phase 3 and Phase 2/3 trials respectively in soft tissue sarcoma and triple-negative breast cancer. INT230-6 has shown up to 95% tumor necrosis, prolonged ...
